Regulatory News:
THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker: ALTER,
eligible for PEA-PME equity savings plans), a company
specializing in in vitro diagnostics and theranostics, announces
the launch of HUMABDIAG, a large-scale antibody bioproduction
research project in Tours.
From July 1, 2021, Theradiag will work with the city of Tours’
academic and industrial ecosystem: its CHRU regional university
hospital, its university and deep-tech antibody company MAbSilico,
on an antibody research and production project co-financed by the
Centre-Val de Loire region to the tune of €450 thousand. This
strategic project is an extension of the global collaboration
agreement with the university of Tours and the creation of a second
site in the Centre-Val de Loire region, announced by the Company in
July and September 2020 respectively.
Every patient, when they develop an immune response to a
pathogen or antigen, produces a broad range of antibodies; this
repertoire of antibodies is specific to that patient. The aim of
the HUMABDIAG project is to seek out, in these directories, the
most efficient antibodies in their binding with their target,
whether that be a viral protein, an immunogenic drug or an
autoantigen within the framework of autoimmune diseases.
More specifically, the approach developed in this project allows
the rapid identification of antibodies of interest and, more
importantly, the identification of their unique genetic sequence.
Based on this sequence, it will then be possible to create a
computer simulation of the binding between the antibody and its
target, and then to reproduce this antibody.
Theradiag will cooperate with the academic players (regional
university hospital and university) in putting the concept and
technology in place: selection and isolation of lymphocytes of
interest and sequencing prior to the computer analysis. MAbSilico
will be responsible for the modeling of the antibodies and
simulations of their binds to their target using their Artificial
Intelligence-based software platform. Theradiag will then transfer
the antibodies of interest onto its platform to produce human
monoclonal antibodies of diagnostic interest. The resulting human
monoclonal antibodies will perfectly reflect the antibodies
actually present in patients and their production will be
standardized. For Theradiag, this important differentiation will
represent major leverage for its strategy and its approach to the
In Vitro Diagnostics (IVD) and Theranostics market.
Theradiag CEO Bertrand de Castelnau commented: “The
launch of this large-scale project called Humabdiag demonstrates
Theradiag’s innovation dynamic. This project in Tours is a
strategic one, as it will enable us, via the manufacturing of human
monoclonal antibodies, to make progress in and further develop our
biotherapy monitoring activity. The value of our partners enhances
our expectations for this project, in which Theradiag will be the
Business Leader. This unique research project will result in the
creation of a new activity that totally complements existing
activities and in the high-quality and economical sourcing of our
materials.”.
REMINDER:
The Extraordinary Shareholders’ Meeting, on the second call,
scheduled for June 10, 2021 is one of your company’s key moments.
Your participation is very important; it provides you with an
opportunity, through your vote, to participate in Theradiag’s
corporate project.
Don’t forget to vote on your financial intermediary’s website
via the Votaccess platform or by giving power or proxy as soon as
possible.
Financial calendar:
- Extraordinary Shareholders’ Meeting on second call, on
Thursday June 10, 2021 - H1 2021 revenue, on Monday July 19,
2021 - H1 2021 results, on Monday September 20, 2021
About Theradiag
Theradiag is the market leader in biotherapy monitoring.
Capitalizing on its expertise in the diagnostics market, the
Company has been developing, manufacturing, and marketing
innovative in vitro diagnostic (IVD) tests for over 30 years.
Theradiag pioneered “theranostics” testing (combining therapy
with diagnosis), which measures the efficacy of biotherapy in the
treatment of chronic inflammatory diseases. Going beyond mere
diagnosis, Theranostics aims to help clinicians set up “customized
treatment” for each patient. This method favors the
individualization of treatment, evaluation of its efficacy and the
prevention of drug resistance. In response to this challenge,
Theradiag develops and markets the CE-marked TRACKER® range, a
comprehensive solution of inestimable medical value.
The Company is based in Marne-la-Vallée, near Paris, has
operations in over 70 countries and employs over 60 people. In
2020, the Company posted revenue of €10.4 million. The Theradiag
share is listed on Euronext Growth Paris (ISIN: FR0004197747) and
is eligible for the French PEA-PME personal equity plan.
For more information about Theradiag, please visit our website:
www.theradiag.com
About the University of Tours Located in the city centers
of Tours and Blois, for the last 50 years the University of Tours
has put training, innovation, professionalism, and the success of
its students at the very heart of its project. With its 7
faculties, 2 institutes of technology and polytechnic engineering
school, it offers its 30,000 students all the benefits of a
multidisciplinary environment. The university is open to the world
and encourages student mobility, taking in more than 3,000
international students each year. It has 36 certified research
units that are recognized in France and around the world: the
University of Tours is thus the Centre-Val de Loire region’s
leading public research institute, making Tours the regional
capital for higher education and research.
About MAbSilico Located in Tours, MAbSilico is a deeptech
company developing and commercializing Artificial
Intelligence-based software for antibody discovery and development.
The software platform can be used for any antibody format, for
therapeutic and biomarker purposes. Only requiring the antibodies
sequences and the target name. MAbSilico software supports
biologists to select, after simulation and modeling in minutes, the
best antibody candidate. The AI-based solutions are on the shelf
and have been validated with biological assays through a formal
approach. Used by biotech and pharma companies, MAbSilico’s
solutions helps their customers to develop the CoVepiT, a covid-19
vaccine in clinical trial, and antibodies that are in pre-clinical
and clinical development stage.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210531005165/en/
Theradiag Bertrand de Castelnau CEO/Managing
Director Tel.: +33 (0)1 64 62 10 12 contact@theradiag.com
NewCap Financial Communications & Investor Relations
Pierre Laurent Quentin Massé Tel.: +33 (0)1 44 71 94
94 theradiag@newcap.eu
NewCap Media Relations Nicolas Mérigeau Tel.: +33
(0)1 44 71 94 98 nmerigeau@newcap.fr
Press contact: Communications department – University of
Tours Email: annesophie.laure@univ-tours.fr Tel.: +33 (0)2 47
36 68 62
MAbSilico Press contact: Email:
contact@mabsilico.com Tel.: +33 (0)7 69 86 09 02
Theradiag (EU:ALTER)
Historical Stock Chart
From Feb 2024 to Mar 2024
Theradiag (EU:ALTER)
Historical Stock Chart
From Mar 2023 to Mar 2024